Nevro

Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Nevro reports strong Q4 earnings, eyes market growth opportunities

Nevro's Q4 2022 performance reflects revenue growth, strong trial rates, and market share gains, with expectations for continued growth.
Challenges include pandemic impact, pricing pressure, and questions on clinical benefits quantification and CEO search progress.
Opportunities lie in market share gains, differentiation through HFX iQ System, and engagement with payers for PDN and NSRBP.
Overall, Nevro anticipates gradual growth throughout 2023, with minimal impact expected from new competitors like Medtronic and Abbott.

Nevro surpasses Q1 expectations, poised for sustained growth ahead

Nevro's Q1 performance exceeded expectations, showcasing strong growth and positive market reception. With a focus on disruptive technologies, new product launches, and market expansion, the company is well-positioned for continued success amidst optimistic market dynamics.

Nevro reports solid Q2 results, focuses on market growth strategies

Nevro's Q2 2023 performance showed revenue growth and focus on market penetration, with challenges in sales force turnover and competition.
Strengths lie in expanded PDN coverage, clinical data emphasis, and reimbursement wins, while opportunities include market growth and enhanced sales productivity.
Addressing challenges through realignment efforts and compensation plans, Nevro aims to leverage market opportunities and drive profitability in the coming months.
Guidance considers turnover impact, territory rebuilding, and sustained business through therapy consultants, positioning Nevro for future growth and success.

Nevro excels in Q3 earnings, eyes growth through innovative therapies

Nevro's Q3 performance reflects strong revenue growth and success in the PDN market, driven by innovative SCS therapy solutions.
The company's strategic focus on commercial execution, market penetration, and operational efficiencies positions them for future success.
Challenges include increasing market penetration, balancing margin expansion with operational efficiency, and careful consideration of acquisitions.
Opportunities lie in leveraging low market penetration, enhancing customer engagement, and collaborating with key experts for continued growth.

Nevro reports solid Q4 revenue growth, eyes market expansion

Nevro's Q4 2023 performance reflects revenue growth driven by PDN sales, with positive EBITDA and strategic acquisitions enhancing market positioning.
While challenges in operational profitability persist, Nevro's focus on market penetration, physician engagement, and salesforce effectiveness present growth opportunities.
Analyst inquiries into market dynamics, competition, and product differentiation underscore the need for Nevro to navigate operational challenges and capitalize on growth prospects.

Nevro surpasses Q1 expectations, eyes market expansion and margin growth

Nevro's Q1 2024 performance exceeded guidance, driven by HFX iQ and increased replacement device candidates, with restructuring efforts to generate savings in 2024.
Strengths include FDA clearance for Nevro1 in SI joint fusion, Android compatibility for HFX iQ, and focus on expanding market penetration.
Challenges include U.S. trials decline, COGS pressure anticipated, and ensuring sales reps are up to speed, while opportunities lie in expanding margins and market penetration.
Overall, Nevro's strategic focus on SI joint fusion products and margin expansion positions them for growth in 2025 and beyond.

Nevro faces revenue decline but pursues strategic growth initiatives

Nevro's Q2 performance reflects revenue challenges but maintains a positive adjusted EBITDA amidst market pressures.
The company's strategic focus on diversification, commercial execution, and exploring strategic options highlights a proactive approach to driving growth.
With a strong cash position and ongoing efforts to navigate challenges and capitalize on opportunities, Nevro is poised for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nevro Corp. engages in the development of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

REDWOOD CITY, Calif., Dec. 13, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that three abstracts for Painful Diabetic Neuropathy (PDN) and Non-Surgical Refractory Back Pain (NSRBP) were accepted for podium presentation at the 2022 North American Neuromodulation Society Annual Meeting (NANS 2022) and will be presented during the late-breaking plenary sessions on January 15, 2022.

Nevro Announces Three Podium Presentations from SENZA-PDN and SENZA-NSRBP Clinical Trials Have Been Accepted for Late-Breaking Abstract Sessions at NANS 2022 Annual Meeting

REDWOOD CITY, Calif., Dec. 10, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D.

Nevro to Present at 40th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Nov. 30, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2021 virtual meeting.

Nevro Announces Two Health Economic Poster Presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2021 Meeting

REDWOOD CITY, Calif., Nov. 29, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced three important clinical data publications for treating Painful Diabetic Neuropathy (PDN) with 10 kHz Therapy, including 12-month data from the landmark SENZA-PDN Randomized Controlled Trial (RCT) published online in Diabetes Care, as well as real-world evidence and a comparative literature review of high vs.

Nevro Announces Three Important Clinical Data Publications for Treating Painful Diabetic Neuropathy with 10 kHz Therapy

The stock price of Nevro, a medical devices company, has seen a large 22% fall in a month. This can largely be attributed to the outcome of a lawsuit against Nevro for patent infringement, with the jury siding with Boston Scientific and finding Nevro to have infringed two of Boston Scientific's.

What's Next For Nevro Stock After A 22% Fall In A Month?

CareDx

Inari Medical

It doesn't take a lot to own a piece of these rapidly growing healthcare businesses.

3 Unstoppable Growth Stocks You Can Buy for Less Than $100 Right Now

Nevro (NVRO) reported wider-than-expected loss during the third quarter with a year-over-year decline in revenues across U.S. and international businesses.

Nevro (NVRO) Q3 Earnings Miss Estimates, Revenues Surpass

Nevro Corp. (NVRO) CEO Keith Grossman on Q3 2021 Results - Earnings Call Transcript

REDWOOD CITY, Calif., Nov. 8, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported its financial results for the third quarter ended September 30, 2021 and provided fourth quarter of 2021 guidance.

Nevro Reports Third Quarter 2021 Financial Results and Provides Fourth Quarter Guidance

Nevro (NYSE:NVRO) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement.

Preview: Nevro's Earnings

Talkspace

U.S. Physical Therapy

Check out these companies utilizing non-pharmaceutical means to optimize America's health.

Binge Watching Dopesick? Here Are 3 Stocks That Involve an Opioid-Free Recovery

Boston Scientific

Dow Jones Newswires: Nevro to pay Boston Scientific $20 million in patent infringement case

REDWOOD CITY, Calif., Nov. 1, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced that a Delaware jury found that Nevro infringed two Boston Scientific patents (7,891,085 and 8,019,439) directed to ways of manufacturing spinal cord stimulation (SCS) leads, which Nevro obtains from a third-party supplier.

Nevro Announces Update in Patent Litigation with Boston Scientific

REDWOOD CITY, Calif., Oct. 25, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D.

Nevro to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

REDWOOD CITY, Calif., Oct. 11, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company will report its financial results for the third quarter ended September 30, 2021 after the market closes on November 8, 2021.

Nevro to Report Third Quarter 2021 Financial Results

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?

Why Is Nevro (NVRO) Up 8.6% Since Last Earnings Report?

REDWOOD CITY, Calif., Aug. 31, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced that Sri Kosaraju has been appointed as a member of the Board of Directors (the "Board"), effective August 31, 2021.

Nevro Announces Director Appointment

REDWOOD CITY, Calif., Aug. 26, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D.

Nevro to Present at Baird 2021 Global Healthcare Conference

REDWOOD CITY, Calif., Aug. 25, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D.

Nevro to Present at Morgan Stanley 19th Annual Global Healthcare Conference

REDWOOD CITY, Calif., Aug. 23, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D.

Nevro to Present at Wells Fargo Virtual Healthcare Conference

Nevro's (NVRO) worldwide revenues rise on a year-over-year basis in Q2 despite pandemic-led business challenges.

Nevro (NVRO) Q2 Earnings Surpass Estimates, Revenues Lag

A narrower-than-expected loss was about the only bright spot in the company's second-quarter results.

Why Nevro Is Falling So Hard Today

Nevro Corp (NYSE: NVRO) posted second-quarter revenue of $102.3 million, +81% Y/Y, missing the consensus of $107.7 million. Total U.S. permanent implant procedures increased 60%, while trial procedures increased 45%, but when compared to Q2 FY19, implant procedures were up 5%, and trial procedures decreased 8%.

Nevro Stock Tanks After Q2 Earnings Miss, Analysts Move To Sidelines

Nevro's (NVRO) CEO Keith Grossman on Q2 2021 Results - Earnings Call Transcript

REDWOOD CITY, Calif., Aug. 4, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported its financial results for the second quarter ended June 30, 2021 and provided third quarter of 2021 guidance.

News for Nevro Stock (NVRO)